Literature DB >> 26314921

In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study.

Polina Putrik1, Sofia Ramiro2, Monika Hifinger3, Andras P Keszei4, Ihsane Hmamouchi5, Maxime Dougados6, Laure Gossec7, Annelies Boonen3.   

Abstract

OBJECTIVES: To investigate patterns in patient-reported and physician-reported disease outcomes in patients with rheumatoid arthritis (RA) from countries with different level of socioeconomic development.
METHODS: Data from a cross-sectional multinational study (COMOrbidities in RA) were used. Contribution of socioeconomic welfare (gross domestic product (GDP); low vs high) of country of residence to physician-reported (tender joint count, swollen joint count (SJC), erythrocyte sedimentation rate, disease activity score based on 28 joints assessment (DAS28)-3v based on these three components and physician global assessment) and patient-reported (modified Health Assessment Questionnaire (mHAQ), patient global assessment and fatigue) disease outcomes was explored in linear regressions, adjusting for relevant confounders.
RESULTS: In total, 3920 patients with RA from 17 countries (30 to 411 patients per country) were included, with mean age of 56 years (SD13) and 82% women. Mean SJC varied between 6.7 (Morocco) and 0.9 (The Netherlands), mean mHAQ ranged between 0.7 (Taiwan) and 1.5 (The Netherlands). Venezuela had the lowest (1.7) and the Netherlands the highest score on fatigue (5.0). In fully adjusted models, lower GDP was associated with worse physician-reported outcomes (1.85 and 2.84 more swollen and tender joints, respectively, and 1.0 point higher DAS28-3v), but only slightly worse performance-based patient-reported outcome (0.15 higher mHAQ), and with better evaluation-based patient-reported outcomes (0.43 and 0.97 points lower on patient global assessment and fatigue, respectively).
CONCLUSIONS: In patients with RA, important differences in physician-reported and patient-reported outcomes across countries were seen, with overall a paradox of worse physician-reported outcomes but better patient-reported outcomes in low-income countries, while results indicate that these outcomes in multinational studies should be interpreted with caution. Research on explanatory factors of this paradox should include non-disease driven cultural factors influencing health. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Epidemiology; Outcomes research; Rheumatoid Arthritis

Mesh:

Year:  2015        PMID: 26314921     DOI: 10.1136/annrheumdis-2015-207738

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

Review 1.  Treatment failure in inflammatory arthritis: time to think about syndemics?

Authors:  Elena Nikiphorou; Heidi Lempp; Brandon A Kohrt
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

Review 2.  Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?

Authors:  Filipe C Araújo; João Gonçalves; João Eurico Fonseca
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

3.  Patient-reported outcomes in Asia: evaluation of the properties of the Rheumatoid Arthritis Impact of Disease (RAID) score in multiethnic Asian patients with rheumatoid arthritis.

Authors:  Peter P Cheung; Manjari Lahiri; Lyn March; Laure Gossec
Journal:  Clin Rheumatol       Date:  2016-12-30       Impact factor: 2.980

Review 4.  Fatigue in Rheumatoid Arthritis.

Authors:  Patricia Katz
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

Review 5.  The changing landscape of biosimilars in rheumatology.

Authors:  Thomas Dörner; Vibeke Strand; Paul Cornes; João Gonçalves; László Gulácsi; Jonathan Kay; Tore K Kvien; Josef Smolen; Yoshiya Tanaka; Gerd R Burmester
Journal:  Ann Rheum Dis       Date:  2016-03-08       Impact factor: 19.103

Review 6.  Serum Vitamin D Level and Rheumatoid Arthritis Disease Activity: Review and Meta-Analysis.

Authors:  Jin Lin; Jian Liu; Michael L Davies; Weiqian Chen
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

7.  Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis.

Authors:  Gloria Crepaldi; Carlo Alberto Scirè; Greta Carrara; Garifallia Sakellariou; Roberto Caporali; Ihsane Hmamouchi; Maxime Dougados; Carlomaurizio Montecucco
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

8.  Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Silvia Rollefstad; George D Kitas; Piet L C M van Riel; Sherine E Gabriel; Anne Grete Semb
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

9.  Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations.

Authors:  Helena Canhão; Ana Maria Rodrigues; Maria João Gregório; Sara S Dias; José António Melo Gomes; Maria José Santos; Augusto Faustino; José António Costa; Cornelia Allaart; Emilia Gvozdenović; Desirée van der Heijde; Pedro Machado; Jaime C Branco; João Eurico Fonseca; José António Silva
Journal:  Front Med (Lausanne)       Date:  2018-03-08

10.  Clinical features and complications of acromegaly at diagnosis are not all the same: data from two large referral centers.

Authors:  Elena V Varlamov; Dan Alexandru Niculescu; Swechya Banskota; Simona Andreea Galoiu; Catalina Poiana; Maria Fleseriu
Journal:  Endocr Connect       Date:  2021-07-05       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.